Ambroxol is a medication indicated for airway secretion clearance therapy. Ambroxol is a secretolytic agent used in the treatment of respiratory diseases associated with viscid or excessive mucus.
- Mechanism
- Curator reviewed
Ambroxol is a mucolytic agent. Excessive Nitric oxide (NO) is associated with inflammatory and some other disturbances of airways function. NO enhances the activation of soluble guanylate cyclase and cGMP accumulation. Ambroxol has been shown to inhibit the NO-dependent activation of soluble guanylate cyclase. It is also possible that the inhibition of NO-dependent activation of soluble guanylate cyclase can suppress the excessive mucus secretion, therefore it lowers the phlegm viscosity and improves the mucociliary transport of bronchial secretions.
- Primary indication
- Ambroxol is indicated for secretolytic therapy in bronchoplmonary disease with abnormal mucus secretion and transport.Curator reviewed · 1 structured indication
- Formula / weight
- C13H18Br2N2O · 378.108 g/mol (avg)
- Also known as
- Bisolvon metabolite vIII · Bromhexine metabolite vIII · Bromhexine-metabolite vIII
- Code names
- NA-872
Resolves to
JBDGDEWWOUBZPM-XYPYZODXSA-NSMILESNC1=C(Br)C=C(Br)C=C1CN[C@H]1CC[C@H](O)CC1What you can answer from here — as of August 30, 2026
Which drugs share a target with Ambroxol, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account